265 related articles for article (PubMed ID: 18195562)
1. Illicit drug use and HIV treatment outcomes in a US cohort.
Cofrancesco J; Scherzer R; Tien PC; Gibert CL; Southwell H; Sidney S; Dobs A; Grunfeld C
AIDS; 2008 Jan; 22(3):357-65. PubMed ID: 18195562
[TBL] [Abstract][Full Text] [Related]
2. Gender differences in illicit substance use among middle-aged drug users with or at risk for HIV infection.
Hartel DM; Schoenbaum EE; Lo Y; Klein RS
Clin Infect Dis; 2006 Aug; 43(4):525-31. PubMed ID: 16838244
[TBL] [Abstract][Full Text] [Related]
3. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users.
Baum MK; Rafie C; Lai S; Sales S; Page B; Campa A
J Acquir Immune Defic Syndr; 2009 Jan; 50(1):93-9. PubMed ID: 19295339
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and factors associated with dry skin in HIV infection: the FRAM study.
Lee D; Benson CA; Lewis CE; Grunfeld C; Scherzer R
AIDS; 2007 Oct; 21(15):2051-7. PubMed ID: 17885295
[TBL] [Abstract][Full Text] [Related]
5. The transition from injection to non-injection drug use: long-term outcomes among heroin and cocaine users in New York City.
Des Jarlais DC; Arasteh K; Perlis T; Hagan H; Heckathorn DD; Mcknight C; Bramson H; Friedman SR
Addiction; 2007 May; 102(5):778-85. PubMed ID: 17506155
[TBL] [Abstract][Full Text] [Related]
6. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection.
Lucas GM; Cheever LW; Chaisson RE; Moore RD
J Acquir Immune Defic Syndr; 2001 Jul; 27(3):251-9. PubMed ID: 11464144
[TBL] [Abstract][Full Text] [Related]
7. Drug use and other risk factors related to lower body mass index among HIV-infected individuals.
Quach LA; Wanke CA; Schmid CH; Gorbach SL; Mwamburi DM; Mayer KH; Spiegelman D; Tang AM
Drug Alcohol Depend; 2008 May; 95(1-2):30-6. PubMed ID: 18243579
[TBL] [Abstract][Full Text] [Related]
8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
9. The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program.
Raffa JD; Grebely J; Tossonian H; Wong T; Viljoen M; Khara M; Mead A; McLean M; Duncan F; Petkau AJ; DeVlaming S; Conway B
Drug Alcohol Depend; 2007 Jul; 89(2-3):306-9. PubMed ID: 17383117
[TBL] [Abstract][Full Text] [Related]
10. Rate and predictors of self-chosen drug discontinuations in highly active antiretroviral therapy-treated HIV-positive individuals.
Murri R; Guaraldi G; Lupoli P; Crisafulli R; Marcotullio S; von Schloesser F; Wu AW
AIDS Patient Care STDS; 2009 Jan; 23(1):35-9. PubMed ID: 19183079
[TBL] [Abstract][Full Text] [Related]
11. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City.
Des Jarlais DC; Arasteh K; Perlis T; Hagan H; Abdul-Quader A; Heckathorn DD; McKnight C; Bramson H; Nemeth C; Torian LV; Friedman SR
AIDS; 2007 Jan; 21(2):231-5. PubMed ID: 17197815
[TBL] [Abstract][Full Text] [Related]
12. Heroin Use and HIV Disease Progression: Results from a Pilot Study of a Russian Cohort.
Edelman EJ; Cheng DM; Krupitsky EM; Bridden C; Quinn E; Walley AY; Lioznov DA; Blokhina E; Zvartau E; Samet JH
AIDS Behav; 2015 Jun; 19(6):1089-97. PubMed ID: 25413642
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal patterns of illicit drug use, antiretroviral therapy exposure and plasma HIV-1 RNA viral load among HIV-positive people who use illicit drugs.
Liang J; Nosova E; Reddon H; Nolan S; Socías E; Barrios R; Milloy MJ
AIDS; 2020 Jul; 34(9):1389-1396. PubMed ID: 32590435
[TBL] [Abstract][Full Text] [Related]
14. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
15. Improvements in HIV treatment outcomes among indigenous and non-indigenous people who use illicit drugs in a Canadian setting.
Milloy MJ; King A; Kerr T; Adams E; Samji H; Guillemi S; Wood E; Montaner J
J Int AIDS Soc; 2016; 19(1):20617. PubMed ID: 27094914
[TBL] [Abstract][Full Text] [Related]
16. HIV treatment in drug abusers: impact of alcohol use.
Miguez MJ; Shor-Posner G; Morales G; Rodriguez A; Burbano X
Addict Biol; 2003 Mar; 8(1):33-7. PubMed ID: 12745413
[TBL] [Abstract][Full Text] [Related]
17. Sexual dysfunction in men who abuse illicit drugs: a preliminary report.
Bang-Ping J
J Sex Med; 2009 Apr; 6(4):1072-1080. PubMed ID: 18093094
[TBL] [Abstract][Full Text] [Related]
18. Abuse and resilience in relation to HAART medication adherence and HIV viral load among women with HIV in the United States.
Dale S; Cohen M; Weber K; Cruise R; Kelso G; Brody L
AIDS Patient Care STDS; 2014 Mar; 28(3):136-43. PubMed ID: 24568654
[TBL] [Abstract][Full Text] [Related]
19. Experience of pain among women with advanced HIV disease.
Richardson JL; Heikes B; Karim R; Weber K; Anastos K; Young M
AIDS Patient Care STDS; 2009 Jul; 23(7):503-11. PubMed ID: 19534600
[TBL] [Abstract][Full Text] [Related]
20. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
